Your browser doesn't support javascript.
loading
Non-clinical, quality and environmental impact assessments of cell and gene therapy products: Report on the 5th Asia Partnership Conference of Regenerative Medicine - April 7, 2022.
Tanaka, Toshimitsu; Karasawa, Hiroshi; Yasumoto, Masahiko; Choi, Byung Hyune; Chang, Ryan; Komuro, Masato; Miyano, Masaaki; Moriya, Yuu; Muthusamy, Sasikumar; Okubo, Shingo; Takakura, Koji; Tsurumaki, Yoshie; Watanabe, Takeshi; Wen, Karen; Yoneda, Tomohiro; Yuan, Ta-Tung; Nomura, Masayuki.
Afiliación
  • Tanaka T; Astellas Pharma Inc., Tokyo, Japan. Electronic address: toshimitsu.tanaka@astellas.com.
  • Karasawa H; Daiichi Sankyo Co., Ltd., Tokyo, Japan. Electronic address: karasawa.hiroshi.vr@daiichisankyo.co.jp.
  • Yasumoto M; NanoCarrier Co., Ltd., Tokyo, Japan. Electronic address: mshkysmt@outlook.com.
  • Choi BH; Council for Advanced Regenerative Medicine and Inha University College of Medicine, Incheon, South Korea.
  • Chang R; Acepodia Inc., Taipei, Taiwan.
  • Komuro M; Novartis Pharma K.K., Tokyo, Japan.
  • Miyano M; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
  • Moriya Y; Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
  • Muthusamy S; NIBR, Preclinical Safety, Novartis Healthcare private limited, Hyderabad, India.
  • Okubo S; Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
  • Takakura K; Astellas Pharma Inc., Tsukuba, Japan.
  • Tsurumaki Y; Novartis Pharma K.K., Tokyo, Japan.
  • Watanabe T; Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
  • Wen K; GenomeFrontier Therapeutics, Inc., Taipei, Taiwan.
  • Yoneda T; Novartis Pharma K.K., Tokyo, Japan.
  • Yuan TT; TFBS Bioscience Inc., Taipei, Taiwan.
  • Nomura M; Asahi Kasei Corporation, Tokyo, Japan.
Cytotherapy ; 25(7): 683-698, 2023 07.
Article en En | MEDLINE | ID: mdl-37097265
ABSTRACT
The 5th Asia Partnership Conference of Regenerative Medicine (APACRM) was held online on April 7, 2022 to promote regulatory harmonization of regenerative medicine products throughout Asia. The recognition of domestic regulatory guidelines within each country and region and the underpinning rationales are important initial steps toward the harmonization of regulations. The 5th APACRM featured open dialog regarding non-clinical, quality and environmental impact assessment settings for cell and gene therapy products through presentations from the industry and panel discussions with regulatory agencies. The latest updates on regenerative medicine fields in each country and region were also introduced. This paper summarizes the proceedings of the 5th APACRM for public dissemination to foster future discussion.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Medicina Regenerativa / Ambiente Tipo de estudio: Guideline / Qualitative_research País/Región como asunto: Asia Idioma: En Revista: Cytotherapy Asunto de la revista: TERAPEUTICA Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Medicina Regenerativa / Ambiente Tipo de estudio: Guideline / Qualitative_research País/Región como asunto: Asia Idioma: En Revista: Cytotherapy Asunto de la revista: TERAPEUTICA Año: 2023 Tipo del documento: Article